U.S. Markets closed

Genentech: Omalizumab met its primary endpoint in Phase III trial, ASTERIA lll

Genentech, a member of the Roche Group announced results from a Phase III trial, ASTERIA II, which demonstrated that omalizumab met its primary endpoint in patients with moderate to severe chronic idiopathic urticaria, CIU, who remained symptomatic despite treatment with approved H1 antihistamine doses.